Regeneron Pharmaceuticals has gained FDA approval for its bispecific antibody Lynozyfic (linvoseltamab) targeting BCMA in relapsed and refractory multiple myeloma, providing dosing flexibility over competitors. Concurrently, novel studies provide deeper understanding of CAR-T therapies targeting BCMA in multiple myeloma, elucidating immune correlates associated with FDA-approved products. These advances mark significant progress in immunotherapeutic approaches for hematologic malignancies.